Form 4: Bicara Therapeutics CLO Sells Shares After Option Exercise

Bicara Therapeutics' Chief Legal Officer, Lara Meisner, exercised stock options and immediately sold the resulting shares on September 15, 2025, under a pre-arranged trading plan.

Summary

• Lara Meisner, Chief Legal Officer of Bicara Therapeutics Inc. (BCAX), reported transactions on September 15, 2025.
• Meisner exercised stock options to acquire 15,829 shares of common stock at an exercise price of $5.45 per share.
• Concurrently, Meisner sold all 15,829 newly acquired shares of common stock at a weighted average price of $11.49 per share.
• These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2024.
• Following these transactions, Meisner beneficially owns 0 shares of common stock directly.
• Meisner retains beneficial ownership of 142,468 stock options (54,769 and 87,699 options respectively) with an exercise price of $5.45.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While it's an insider sale, it was pre-planned under a Rule 10b5-1 plan, which reduces negative speculation. The officer also realized a significant profit, indicating a positive personal financial outcome from their equity holdings.

Positives

• The Chief Legal Officer realized a significant profit from the exercise and sale of stock options, indicating personal financial benefit from company equity.
• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, which demonstrates structured and compliant insider trading practices.
• The sale price of $11.49 per share is more than double the exercise price of $5.45 per share, highlighting a substantial gain for the reporting person.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived negatively by investors as it reduces the officer's direct equity stake in the company.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding the company's future performance or strategic direction, focusing solely on past insider transactions.

Management Comments

• This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2024.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction and does not provide information relevant to broader industry trends or competitive landscape analysis.

Corporate Governance

Stakeholder Impact

• Shareholders: May view the insider sale with mixed feelings; some might see it as a lack of confidence, while others will recognize it as a pre-planned, routine event. The profit realized by the officer could be seen as a positive sign of equity value.
• Management: The Chief Legal Officer has reduced direct equity ownership but still holds a significant number of unexercised options.

Next Steps

• Remaining stock options will continue to vest according to their respective schedules, subject to the reporting person's continued service.

Key Dates

Keywords

Bicara Therapeutics, BCAX, Insider Trading, Form 4, Stock Options, Rule 10b5-1, Lara Meisner, Chief Legal Officer, Equity Sale